®

PRESS RELEASE

www.inhibitex.com

FOR IMMEDIATE RELEASE

INHIBITEX ANNOUNCES PROPOSED PUBLIC OFFERING

ATLANTA, GA – April 6, 2011 — Inhibitex, Inc. (Nasdaq: INHX) today announced its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including a Phase 2 clinical trial for INX-189, a nucleotide polymerase inhibitor that it is developing for the treatment of chronic hepatitis C infections, and research and development expenses related to its other development programs.

Deutsche Bank Securities Inc. is acting as sole book-running manager. The offering is being made pursuant to an effective shelf registration statement that Inhibitex filed with the Securities and Exchange Commission (“SEC”) on March 30, 2010. A prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the prospectus supplement and the prospectus relating to these securities may be obtained by contacting Deutsche Bank Securities, Inc., Attn: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311, Telephone number: 800-503-4611, Email: prospectus.cpdg@db.com. Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock of Inhibitex, Inc., nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inhibitex

Inhibitex, Inc. is a clinical stage biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase 2 clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1 clinical development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM^® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.

Inhibitex^® and MSCRAMM^® are registered trademarks of Inhibitex, Inc.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimate,” “plans,” “expects,” “we believe,” “we intend,” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “potential,” “could,” “may,” or similar expressions. These statements involve substantial risks and uncertainties, including risks relating to the completion of the registered public offering, including the satisfaction of customary closing conditions, the use of the anticipated proceeds from the offering, the Company’s need to raise additional operating capital in the future, the Company’s history of losses, risks and costs of drug development, risk of regulatory approvals, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for the Company’s products if any are approved for marketing, reliance on key personnel and other cautionary statements contained in the Company’s public filings made with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, as filed with the SEC on March 16, 2011. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.